Previous 10 | Next 10 |
--News Direct-- Dermata Therapeutics chairman and CEO Gerald Proehl takes Proactive's Stephen Gunnion through the clinical-stage biotechnology company's pipeline of treatments focused on medical and aesthetic skin conditions. He says the company's lead candidate DMT310 will move into ...
2023-05-10 08:19:32 ET CTI BioPharma ( CTIC ) +84% to acquire CTI BioPharma for $9.10 per share. Upstart Holdings ( UPST ) +36% Q1 earnings call release Insignia Systems ( ISIG ) +27% Q1 earnings call release Microvast Holdings ( MVST ) +2...
2023-05-03 08:34:28 ET Aptorum Group ( APM ) +153% . Akanda ( AKAN ) +113% . ImmunoGen ( IMGN ) +96% surges ~95% as ovarian cancer drug Elahere shows survival benefit in confirmatory trial. Kiromic BioPharma, Inc. ( KRBP ) +59% ....
2023-04-24 10:08:54 ET Gainers: IN8bio ( INAB ) +121% . IDEAYA Biosciences ( IDYA ) +27% . ZyVersa Therapeutics ( ZVSA ) +26% . Koninklijke Philips ( PHG ) +15% . Kiora Pharmaceuticals ( KPRX ) +9% . Losers: Scilex H...
2023-04-21 13:53:45 ET Gainers: Presto Automation ( PRST ) +49% . CBL International Limited ( BANL ) +34% . EyePoint Pharmaceuticals EYPT +31% . Asset Entities ( ASST ) +25% . ContextLogic ( WISH ) +24% . Mullen Automotive ( MU...
2023-04-21 10:03:36 ET Gainers: EyePoint Pharmaceuticals ( EYPT ) +19% . Tenaya Therapeutics ( TNYA ) +21% . Community Health Systems ( CYH ) +11% . NovaBay Pharmaceuticals ( NBY ) +11% . Aziyo Biologics ( AZYO ) +8% . Loser...
2023-04-20 10:04:03 ET Gainers: Augmedix ( AUGX ) +67% . CNS Pharmaceuticals ( CNSP ) +65% . Petros Pharmaceuticals ( PTPI ) +36% . ContraFect ( CFRX ) +20% . Dermata Therapeutics ( DRMA ) +14% . Losers: Windtree Therapeut...
2023-04-20 06:57:55 ET Shares of medical dermatology company Dermata Therapeutics ( NASDAQ: DRMA ) jumped ~28% in the pre-market trading Thursday after issuing updates on its late-stage clinical program for acne candidate DMT310. Aiming to discuss a Phase 3 trial for DMT310 ...
- FDA agrees that Dermata's CMC procedures and controls support the initiation of Phase 3 studies- - Dermata also submitted an end of phase 2 meeting package to the FDA - SAN DIEGO, CA / ACCESSWIRE / April 20, 2023 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) ("Dermata" or...
2023-04-19 08:21:42 ET Allarity Therapeutics ( ALLR ) -33% . Femasys ( FEMY ) -25% anounces $3.9 million registered direct offering. Oblong ( OBLG ) -21% . Gamida Cell ( GMDA ) -16% on public offering . United Insurance Holdings ( ...
News, Short Squeeze, Breakout and More Instantly...
Dermata Therapeutics Inc. Company Name:
DRMA Stock Symbol:
NASDAQ Market:
Dermata Therapeutics Inc. Website:
SAN DIEGO, CA / ACCESSWIRE / May 17, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata," or the "Company"), a late-stage biotechnology company focused on the treatment of medical and aesthetic skin diseases and conditions, today announced the entry into definitive agreement...
- DMT310 Phase 3 Spongilla Treatment of Acne Research (STAR-1) clinical trial enrollment remains on track - - Dermata continues discussions with potential botulinum toxin partners for DMT410 - - Received issuance of Japanese patent for DMT410 for the treatment of hyperhidrosis - SAN...
AlloVir Inc. (ALVR) is expected to report $-0.16 for Q1 2024 Inter & Co. Inc. (INTR) is expected to report $0.08 for Q1 2024 Array Technologies Inc. (ARRY) is expected to report $-0.06 for Q1 2024 Sphere 3D Corp. (ANY) is expected to report $-0.23 for Q1 2024 Alpine Immune Sci...